Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.
Hum Vaccin Immunother. 2021 Dec 2;17(12):5638-5645. doi: 10.1080/21645515.2021.1996151. Epub 2021 Nov 19.
Community-acquired pneumonia (CAP) is a lower respiratory tract infection. It is one of the commonest infectious diseases and the third leading cause of death worldwide. However, the epidemiological profiles of CAP in southeastern China are unknown. Data of inpatients and outpatients diagnosed with CAP from January 1, 2015 to December 31, 2020 were obtained from the National Healthcare Big Data in Fuzhou (Fuzhou Database). This database covers medical data from 37 hospitals and 159 community health service stations. The incidence rate, treatment pattern, and direct medical costs of CAP were assessed using clinical data. A total of 8,156,237 patients were enrolled, with a mean age of 33.72 ± 20.88 years. The overall incidence rate of CAP was 3.13 (95% confidence interval [CI]: 3.11-3.15) per 1000 person-years (PY), with 15.97 (95% CI: 15.85-16.08) per 1000 PY in children below 5 years old and 2.62 (95% CI: 2.57-2.66) per 1000 PY in the elderly ≥60 years. The cost per outpatient was $242.83 ± 341.62, and the cost per inpatient was $4,530.4 ± 9,151.68. The three most used therapeutic drugs in patients with CAP are cefotaxime, moxifloxacin, and azithromycin. In addition, despite the ability of both imported and domestic pneumococcal conjugate vaccines to reduce the incidence rate of CAP, the current vaccination coverage rates were relatively low. We suggest that more attention should be paid to the disease burden of CAP, especially due to its great economic burden in China.
社区获得性肺炎（CAP）是一种下呼吸道感染。它是最常见的传染病之一，也是全球第三大致死原因。然而，中国东南部 CAP 的流行病学特征尚不清楚。本研究从国家医疗健康大数据平台福州分平台（福州数据库）中获取了 2015 年 1 月 1 日至 2020 年 12 月 31 日期间诊断为 CAP 的住院和门诊患者的数据。该数据库涵盖了来自 37 家医院和 159 家社区卫生服务站的医疗数据。使用临床数据评估 CAP 的发病率、治疗模式和直接医疗费用。共纳入 8156237 例患者，平均年龄为 33.72±20.88 岁。CAP 的总发病率为 3.13（95%置信区间[CI]：3.11-3.15）/1000人年（PY），5 岁以下儿童为 15.97（95%CI：15.85-16.08）/1000PY，≥60 岁老年人为 2.62（95%CI：2.57-2.66）/1000PY。门诊患者的每次就诊费用为 242.83±341.62 美元，住院患者的每次就诊费用为 4530.4±9151.68 美元。CAP 患者使用最多的三种治疗药物是头孢噻肟、莫西沙星和阿奇霉素。此外，尽管进口和国产肺炎球菌结合疫苗都能降低 CAP 的发病率，但目前的疫苗接种率相对较低。我们建议更多地关注 CAP 的疾病负担，特别是在中国其具有巨大的经济负担。
